OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Other Current Assets

Last Annual Value

1.79M

3-Year CAGR

29%

5-Year CAGR

5%

10-Year CAGR

2%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Other Current Assets

OKUR · NASDAQ
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.79M
N/A-21.7%N/A 
0.00
N/AN/AN/A
1.39M
77.1%13.8%8.8%
5.02M
-2.3%-18.2%N/A
3.50K
-6.2%N/A-31.5%
2.50M
-10.0%-11.0%N/A
357.00K
16.5%-4.2%26.2%
2.28M
-22.8%-26.9%N/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47